PT - JOURNAL ARTICLE AU - Schaare, Donna AU - Lusk, Laina AU - Karlin, Alexis AU - Kaufman, Michael C. AU - Magielski, Jan AU - Sarasua, Sara M. AU - Allison, Kendra AU - Boccuto, Luigi AU - Helbig, Ingo TI - A Longitudinal Exploration of <em>CACNA1A</em>-related Hemiplegic Migraine in Children AID - 10.1101/2024.06.14.24308953 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.14.24308953 4099 - http://medrxiv.org/content/early/2024/06/15/2024.06.14.24308953.short 4100 - http://medrxiv.org/content/early/2024/06/15/2024.06.14.24308953.full AB - Introduction Since the initial description of CACNA1A-related hemiplegic migraine (HM), the phenotypic spectrum has expanded from mild episodes in neurotypical individuals to potentially life-threatening events frequently seen in individuals with developmental and epileptic encephalopathies. However, the overall longitudinal course throughout childhood remains unknown.Methods We analyzed HM and seizure history in individuals with CACNA1A-related HM, delineating frequency and severity of events in monthly increments through a standardized approach. Combining these data with medication prescription information, we assessed the response of HM to different agents.Results Our cohort involved 15 individuals between 3 and 29 years (163 patient years) and included 11 unique and two recurrent variants (p.R1349Q and p.V1393M; both n=2). The age of first confirmed HM ranged from 14 months to 13 years (average 3 years). 25% of all HM events were severe (lasting &gt;3 days) and 73% of individuals had at least 1 severe occurrence. Spacing of HM events ranged from 1 month to 14 years and changes in HM severity over time of showed increases or decreases of &gt;2 severity levels in 12/122 events. Eight individuals had epilepsy, but severity of epilepsy did not correlate with frequency and severity of HM events. While levetiracetam (n=6) and acetazolamide (n=5) were the most frequently used medications, they did not show efficacy in HM prevention or HM severity reduction. However, verapamil (n=3) showed efficacy in preventing HM episodes (OR 2.68, CI 1.39-5.67).Significance The longitudinal course of CACNA1A-related HM lacks recognizable patterns for timing and severity of HM events or correlation with seizure patterns. Our data underscores the unpredictability of CACNA1A-related HM, highlighting the need for close surveillance for reoccurring HM events even in individuals with symptom-free periods.Key points24% of hemiplegic migraines (HM) in CACNA1A-related disorders are severe, involving cerebral edema and greater than 4 days to recoverTiming and severity of HM are unpredictable, with large changes in severity between events, and age of onset ranging from 1-13 yearsEpilepsy occurred in 53% of individuals, with neither the timing nor severity of seizures correlated with HMCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by R01-NS127830.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Children's Hospital of Philadelphia gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData and computer code available via github on request.